sarilumab   

GtoPdb Ligand ID: 7999

Synonyms: Kevzara® | REGN88 | SAR153191
sarilumab is an approved drug (EMA & FDA (2017))
Compound class: Antibody
Comment: Sarilumab is a monoclonal antibody directed against the interleukin 6 receptor (IL6R).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequence BLAST search using the heavy and light chain variable regions of sarilumab provides 100% matches to sequences covered by patent US7582298 [3], and to the antibody with designation VQ8F11-21.
Immunopharmacology Comments
In clinical trial sarilumab significantly reduced the signs and symptoms of RA and improved physical function [1-2,4]. A notable side-effect is immune suppression leading to susceptibility to infection.
Immunopharmacology Disease
Disease X-Refs Comment References
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
FDA approved therapeutic for RA (May 2017).
Ankylosing spondylitis Disease Ontology: DOID:7147
Clinical trial in ankylosing spondylitis was terminated.
Uveitis Disease Ontology: DOID:13141
Completed Phase 2 clinical trial for non-infectious uveitis (see NCT01900431).